GLP-1 receptor agonists have transformed obesity treatment—but rising demand, high costs, and insurance hurdles have complicated clinical decision-making. In this timely session, Dr. Courtney Younglove will review the latest evidence behind GLP-1 therapies for obesity, discuss the role and regulation of compounded medications, and address real-world challenges related to access and affordability. Clinicians will leave with practical strategies to navigate treatment options, personalize care, and advocate for patients in a rapidly evolving landscape.

Courtney Younglove, MD, FOMA, FACOG, DABOM, is a dual board-certified obesity medicine specialist and OB/GYN, and the founder of Heartland Weight Loss. With extensive experience in hormonal health, metabolism, and midlife care, she specializes in helping women achieve sustainable weight loss through evidence-based, compassionate medical treatment. Dr. Younglove is a Fellow of the Obesity Medicine Association and a recognized leader in integrating obesity and women’s health care to improve long-term outcomes.